Shares of Health Catalyst, Inc. (NASDAQ:HCAT – Get Rating) have been given an average recommendation of “Moderate Buy” by the sixteen research firms that are currently covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $18.53.
HCAT has been the subject of a number of recent analyst reports. Wells Fargo & Company started coverage on Health Catalyst in a report on Monday, October 31st. They set an “equal weight” rating and a $10.00 target price for the company. SVB Leerink dropped their target price on Health Catalyst from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Wednesday, November 9th. Raymond James lowered their price objective on Health Catalyst from $20.00 to $15.00 and set a “strong-buy” rating for the company in a research report on Thursday, November 10th. BTIG Research lowered their price objective on Health Catalyst to $17.00 in a research report on Tuesday, November 15th. Finally, Royal Bank of Canada downgraded Health Catalyst from an “outperform” rating to a “sector perform” rating and lowered their price objective for the company from $19.00 to $9.00 in a research report on Tuesday, October 25th.
Health Catalyst Stock Performance
NASDAQ:HCAT opened at $10.30 on Monday. The company has a market capitalization of $563.94 million, a PE ratio of -3.50 and a beta of 1.24. The company has a 50 day simple moving average of $9.62 and a two-hundred day simple moving average of $11.81. The company has a debt-to-equity ratio of 0.51, a quick ratio of 4.87 and a current ratio of 4.87. Health Catalyst has a fifty-two week low of $6.40 and a fifty-two week high of $41.28.
Health Catalyst (NASDAQ:HCAT – Get Rating) last issued its quarterly earnings data on Tuesday, November 8th. The company reported ($0.45) earnings per share for the quarter, beating the consensus estimate of ($0.53) by $0.08. Health Catalyst had a negative return on equity of 19.05% and a negative net margin of 55.42%. The business had revenue of $68.35 million for the quarter, compared to analysts’ expectations of $66.85 million. Research analysts anticipate that Health Catalyst will post -1.66 earnings per share for the current year.
Insider Buying and Selling
In related news, CEO Daniel D. Burton bought 197,078 shares of the business’s stock in a transaction dated Friday, November 11th. The shares were purchased at an average cost of $10.14 per share, with a total value of $1,998,370.92. Following the completion of the purchase, the chief executive officer now owns 900,140 shares in the company, valued at approximately $9,127,419.60. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders have sold a total of 1,549 shares of company stock valued at $15,928 over the last ninety days. Company insiders own 1.50% of the company’s stock.
Institutional Investors Weigh In On Health Catalyst
Institutional investors have recently modified their holdings of the stock. Corient Capital Partners LLC bought a new position in shares of Health Catalyst during the second quarter valued at $157,000. Engineers Gate Manager LP lifted its holdings in shares of Health Catalyst by 128.9% during the first quarter. Engineers Gate Manager LP now owns 117,471 shares of the company’s stock valued at $3,070,000 after purchasing an additional 66,141 shares in the last quarter. Ashford Capital Management Inc. lifted its holdings in shares of Health Catalyst by 75.1% during the second quarter. Ashford Capital Management Inc. now owns 828,822 shares of the company’s stock valued at $12,010,000 after purchasing an additional 355,470 shares in the last quarter. Madison Asset Management LLC bought a new position in shares of Health Catalyst during the first quarter valued at $2,069,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Health Catalyst by 51.4% during the first quarter. Parkman Healthcare Partners LLC now owns 79,746 shares of the company’s stock valued at $2,084,000 after purchasing an additional 27,068 shares in the last quarter. 90.55% of the stock is owned by hedge funds and other institutional investors.
Health Catalyst Company Profile
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations. Its offerings include data and analytics platform, a commercial-grade data and analytics platform for the healthcare sector; AI and data science, providing integration of AI into existing business intelligence tools, increasing analytics accuracy; population health management identifies improvement across the care continuum as well as actionable guidance for success and automated workflows; financial transformation providing costing and labor productivity insights and revenue capture; quality and safety improvement using clinical quality and patient safety data, analytics, and expert services; and national data ecosystem for thought leadership and mutual knowledge exchange to transform care delivery through next-gen insights.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Health Catalyst, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Health Catalyst wasn’t on the list.
While Health Catalyst currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
